Akihiko Soyama, Susumu Eguchi, Mitsuhisa Takatsuki, Tatsuki Ichikawa, Masako Moriuchi, Hiroyuki Moriuchi, Tatsufumi Nakamura, Yoshitsugu Tajima, Takashi Kanematsu – 23 April 2008 – This report describes a patient who developed human T‐cell leukemia virus type I–associated myelopathy (HAM) following a living‐donor liver transplantation (LDLT) for liver cirrhosis due to hepatitis C virus (HCV) infection. Both the recipient and the living donor (his sister) were human T‐cell leukemia virus type I (HTLV‐I) carriers.

Katrina J. Allen, Nicole A. Mifsud, Robert Williamson, Patrick Bertolino, Winita Hardikar – 23 April 2008 – Liver cell transplantation in humans has been impeded by invariable loss of the graft. It is unclear whether graft loss is due to an immune response against donor hepatocytes. Transplantation with ABO‐matched liver cells was performed in a patient with Crigler‐Najjar type 1. After successful engraftment, there was a gradual loss of graft function.

Matteo Cescon, Gian Luca Grazi, Alessandro Cucchetti, Matteo Ravaioli, Giorgio Ercolani, Marco Vivarelli, Antonietta D'Errico, Massimo Del Gaudio, Antonio Daniele Pinna – 23 April 2008 – Advanced donor age is a risk factor for poor outcome in liver transplantation (LT). We reviewed 553 consecutive transplants according to donor age categories [group 1 (n = 173): <50 years; group 2 (n = 96): 50–59 years; group 3 (n = 132): 60–69 years; group 4 (n = 111): 70–79 years; group 5 (n = 41): ≥80 years]. Clinical parameters were comparable between groups.

Ranjeeta Bahirwani, Mical S. Campbell, Tim Siropaides, James Markmann, Kim Olthoff, Abraham Shaked, Roy D. Bloom, K. Rajender Reddy – 23 April 2008 – Pre–liver transplant renal dysfunction is associated with decreased survival following transplantation and is also a prognostic indicator of posttransplant chronic kidney disease.

Kristin L. Mekeel, Adyr A. Moss, Kunam S. Reddy, David D. Douglas, Hugo E. Vargas, Elizabeth J. Carey, Thomas J. Byrne, M. E. Harrison, Jorge Rakela, David C. Mulligan – 23 April 2008 – In the current Model for End‐Stage Liver Disease system, patients with polycystic liver disease (PCLD) who have a poor quality of life secondary to their massive hepatomegaly are no longer competitive for a deceased donor liver transplant if their liver function is well preserved.

James D. Perkins – 23 April 2008

Derek DuBay, Rob J. Smith, Kenneth G. Qiu, Gary A. Levy, Leslie Lilly, George Therapondos – 23 April 2008 – The purpose of this study is to review the clinical experience with sirolimus immunosuppression in liver transplant patients with calcineurin inhibitor–induced chronic renal insufficiency. The study design is a case‐control retrospective series. Fifty‐seven liver transplant patients with renal insufficiency that were started on sirolimus at greater than 90 days postoperatively and treated for more than 90 days were identified.

Shimon Kusne, Manjushree Gautam – 23 April 2008

Estella M. Alonso – 23 April 2008

Cataldo Doria, Elia S. Elia, Yoogoo Kang, Albert Adam, Anik Desormeaux, Carlo Ramirez, Adam Frank, Fabrizio di Francesco, Jay H. Herman – 23 April 2008 – Acute hypotensive transfusion reactions are newly characterized transfusion reactions in which hypotension is the prominent feature. The pathophysiology of acute hypotensive transfusion reactions is related to the bradykinin function and its metabolism.